DENVER — The first randomized controlled trial of furosemide for preterm infants at high risk for bronchopulmonary dysplasia found an increased risk for electrolyte adverse events but no greater risk for overall safety events.
Researchers presented the findings during the Pediatric Academic Societies Meeting.
The study found there was no difference in hearing loss, nephrocalcinosis, bronchopulmonary dysplasia (BPD) or death.
Rachel G. Greenberg, MD, MB, MHS, associate professor of pediatrics at the Duke University School of Medicine and member of the Duke Clinical Research Institute, said
First RCT evaluates safety, efficacy of furosemide in preemies with BPD risk
DENVER — The first randomized controlled trial of furosemide for preterm infants at high risk for bronchopulmonary dysplasia found an increased risk for electrolyte adverse events but no greater risk for overall safety events.
Researchers presented the findings during the Pediatric Academic Societies Meeting.
The study found there was no difference in hearing loss, nephrocalcinosis, bronchopulmonary dysplasia (BPD) or death.
Rachel G. Greenberg, MD, MB, MHS, associate professor of pediatrics at the Duke University School of Medicine and member of the Duke Clinical Research Institute, said